Glenmark Pharmaceuticals
Update in progressGLENMARK.NS (NSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Glenmark Pharmaceuticals Limited and its subsidiaries develop, manufacture, and market generic medicines, branded and OTC products across India, North America, Europe, and international markets. The company serves dermatology, respiratory, oncology, immunology, pain, hypertension, CNS, cardiology, diabetes, gynecology, gastroenterology, and anti-infectives with injectables, biologics, oral solids, liquids, topicals, and inhalers. Founded 1977, Mumbai. Ryaltris is marketed for seasonal allergic rhinitis.
Company score
- Sentiment
- -0.29
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.34
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.24
- Governance
- -1.42
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.26
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!